Peringatan Keamanan

The most common adverse reactions associated with Ixekizumab treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.

Ixekizumab

DB11569

biotech approved investigational

Deskripsi

Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis.

Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 13 days
Volume Distribusi The mean (geometric CV%) volume of distribution at steady-state was 7.11 L (29%) in subjects with plaque psoriasis.
Klirens (Clearance) 0.39 L/day

Absorpsi

Following a single subcutaneous dose of 160 mg in subjects with plaque psoriasis, ixekizumab reached peak mean (±SD) serum concentrations (Cmax) of 16.2 ±6.6 mcg/mL by approximately 4 days post dose.

Metabolisme

The metabolic pathway of ixekizumab has not been characterized. As a humanized IgG4 monoclonal antibody ixekizumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

670 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Ixekizumab.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Ixekizumab.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ixekizumab.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ixekizumab.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ixekizumab.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ixekizumab.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Ixekizumab.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ixekizumab.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Ixekizumab.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ixekizumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Ixekizumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ixekizumab.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ixekizumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Ixekizumab.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ixekizumab.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ixekizumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Ixekizumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Ixekizumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Ixekizumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ixekizumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Ixekizumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ixekizumab.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Ixekizumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Ixekizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ixekizumab.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ixekizumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Ixekizumab.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ixekizumab.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Ixekizumab.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Ixekizumab.
Cladribine Ixekizumab may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Ixekizumab.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Ixekizumab.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Ixekizumab.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Ixekizumab.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Ixekizumab.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Ixekizumab.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Ixekizumab.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Ixekizumab.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Ixekizumab.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Ixekizumab.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Ixekizumab.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Ixekizumab.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ixekizumab.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Ixekizumab.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Ixekizumab.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Ixekizumab.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Ixekizumab.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Ixekizumab.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Ixekizumab.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Ixekizumab.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Ixekizumab.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Ixekizumab.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Ixekizumab.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Ixekizumab.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Ixekizumab.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Ixekizumab.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ixekizumab.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Ixekizumab.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Ixekizumab.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Ixekizumab.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ixekizumab.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Ixekizumab.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Ixekizumab.
Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Ixekizumab.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Ixekizumab.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ixekizumab.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Ixekizumab.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Ixekizumab.
Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Ixekizumab.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Ixekizumab.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Ixekizumab.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Ixekizumab.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Ixekizumab.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ixekizumab.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ixekizumab.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ixekizumab.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Ixekizumab.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Ixekizumab.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Ixekizumab.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ixekizumab.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Ixekizumab.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Ixekizumab.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Ixekizumab.
Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Ixekizumab.
Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Ixekizumab.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Ixekizumab.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Ixekizumab.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Ixekizumab.
Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ixekizumab.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ixekizumab.
Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Ixekizumab.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Ixekizumab.
Doxorubicin The risk or severity of adverse effects can be increased when Doxorubicin is combined with Ixekizumab.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Ixekizumab.
Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Ixekizumab.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ixekizumab.
Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Ixekizumab.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Ixekizumab.
Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Ixekizumab.

Target Protein

Interleukin-17A IL17A

Referensi & Sumber

Artikel (PubMed)
  • PMID: 25748485
    Dyring-Andersen B, Skov L, Zachariae C: Ixekizumab for treatment of psoriasis. Expert Rev Clin Immunol. 2015 Apr;11(4):435-42. doi: 10.1586/1744666X.2015.1023295. Epub 2015 Mar 8.
  • PMID: 20131262
    Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J: LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010 Apr;62(4):929-39. doi: 10.1002/art.27334.
  • PMID: 11920418
    Bush KA, Farmer KM, Walker JS, Kirkham BW: Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 2002 Mar;46(3):802-5.

Contoh Produk & Brand

Produk: 12 • International brands: 0
Produk
  • Taltz
    Injection, solution • 80 mg/1mL • Subcutaneous • US • Approved
  • Taltz
    Injection, solution • 80 mg/1mL • Subcutaneous • US • Approved
  • Taltz
    Solution • 80 mg / mL • Subcutaneous • Canada • Approved
  • Taltz
    Solution • 80 mg / mL • Subcutaneous • Canada • Approved
  • Taltz
    Injection, solution • 20 mg/0.25mL • Subcutaneous • US • Approved
  • Taltz
    Injection, solution • 40 mg/0.5mL • Subcutaneous • US • Approved
  • Taltz
    Injection, solution • 80 mg • Subcutaneous • EU • Approved
  • Taltz
    Injection, solution • 80 mg • Subcutaneous • EU • Approved
Menampilkan 8 dari 12 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul